Seminar Program Evonik Health Care

Overview

Lipids are some of the most clinically important excipients for drug delivery systems and are especially relevant for RNA-based therapies and mRNA vaccines. As a CDMO partner offering end-to-end solutions, Evonik has decades of experience and expertise in every step of the manufacturing process, including route scouting, process development and optimization, purification, isolation, characterization, scale-up, and commercialization.

This workshop will focus on the growth and use of lipids for drug delivery and provide insight into important steps for success. We will not only outline the role of our novel multivariate models to speed up timelines and increase successful scale-up and transfer to the clinic, but also highlight current advances in leveraging novel lipids, such as randomized PEGs (rPEGs) in LNP-based delivery systems.

Key learnings for participants

Introduction to capabilities necessary to support lipid development and manufacturing
Lipid impurities and their impact on therapeutic effectiveness
LNP formulation opportunities with rPEGs

This event will be jointly hosted by Evonik Health Care and Knauer. We are delighted to welcome our esteemed speakers from Evonik and Knauer, as well as leaders from industry and academia, who will present exciting insights and case studies.

Agenda

08:00 a.m. | Registration & Breakfast

08:30 a.m. | Welcome & Introduction to Evonik Health Care
Cody Yetter
Director Business Development
Evonik Health Care

Dr. Andrea Engel
Global Head, Growth Projects Health Care
Evonik Health Care

09:00 a.m | Lipids, Learnings & Future Opportunities
Dr. Zahra Merchant
Senior Scientist RD&I
Evonik Health Care

09:45 a.m. | New Developments in rPEGs
Dr. Thomas Endres
Head of New Products and Materials
Evonik Health Care

10:15 a.m. | Coffee Break & Networking

10:30 a.m. | Controlled delivery of stabilized mRNA LNP formulations to the respiratory tract: From bench to bedside
Dr. Carsten Rudolph
Co-founder & CEO
ETHRIS GmbH

11:00 a.m. | Next-Generation LNP Mixing Technologies
Janis Fiedler
Product Manager Customized Solutions
Knauer

11:30 a.m. | Developing your LNP Formulation
Dr. Michael Parr
Director of Formulation and Process Development
Evonik Health Care

12:15 p.m. | Q&A and Panel

01:00 p.m. | Lunch & Lab Demo

02:00 p.m. | Wrap-up

Experts

Dr. Andrea Engel
Global Head, Health Care Growth Projects
Evonik Health Care
Vita

Dr. Andrea Engel joined Evonik’s Health Care business line in 2013 and is currently Director Research & Development.

The team focuses on the development and analytics of new oral and parenteral platform technologies for the pharma and food industry as well as the development of cell culture media. One of the main research areas lies in the formulation and bioavailability enhancement of poorly bioavailable drugs and biopharmaceuticals.

Before taking over the current position she held a position as laboratory head and project manager in Innovation Management at Evonik where she has gained experience in developing complex oral and parenteral dosage forms and handling of highly potent active pharmaceutical ingredients.

She received her degree in pharmacy from the University of Frankfurt am Main and her Ph.D. in pharmaceutical technology and biopharmacy from the University of Muenster where she has specialized on the development of drug delivery systems based on bioabsorbable nanoparticles for cancer treatment.

Moreover, she has authored several research papers and patent applications.

Dr. Thomas Endres
Manager New Products & Materials
Evonik Health Care
Vita

Thomas Endres is an expert in polymeric excipients for oral and parenteral dosage forms and has extensive experience in the management of innovation and customer projects.

Thomas joined Evonik in 2012 and has held roles as project manager in the R&D department in Germany, and as biomaterials manager in the U.S.

He studied macromolecular chemistry before completing his doctoral research in polymer chemistry at the Institute of Pharmaceutical Technology at the University of Marburg in Germany.

Dr. Michael Parr
Director Formulation and Process Development
Evonik Health Care
Vita

Dr. Michael “Mike” Parr joined the Production & Technology team of Evonik’s Health Care business line in 2021 as director of formulations and process development for the Vancouver site. Mike is responsible for leading multifunctional teams and ensuring the successful execution of a portfolio of complex customer-funded development programs as part of the parenteral drug delivery solutions business.

Mike has more than 20 years of experience in the pharmaceutical industry including roles at Sitka Biopharma, CDRD Ventures Inc., Angiotech and Biogen Idec. His areas of expertise include liposomal drug delivery systems, formulation, molecular biology, GLP, GMP activities and clinical development. Mike holds a B.Sc. Honours and Ph.D. in Biochemistry and Molecular Biology from The University of British Columbia in the laboratory of Dr. Pieter Cullis and he completed post-doctoral studies at Harvard Medical School.

Details

City/State:: Boston, MA
Country:: USA
Seminar language:: English

Venue

The workshop will take place at:

Evonik Cambridge Innovation Satellite
6^th Floor Event Space
238 Massachusetts Ave
Cambridge, MA 02139, USA

Questions?

Emily Peters
Manager Regional Marketing, North America
Evonik Health Care

+1 732 981 5145 E-Mail